• Intranet
    DARE-NL
    • About
      • DARE-NL
      • What are ATMPs (ENG)
      • More information
      • Wat zijn ATMPs (NL)
      • Meer weten?
    • Activities
      • Workpackage 1
      • Workpackage 2
      • Workpackage 3
      • Workpackage 4
      • Workpackage 5
      • Workpackage 6
      • Workpackage 7
    • People and Partners
      • Organisation
      • Supporting organisations
      • Management Team
      • Project Team
      • Steering Committee
      • Patient Advisory Board
      • Patient Participation Review Committee
      • Scientific Advisory Board
      • Vacancies
    • Courses & Events
      • Course directory
      • Submit new course
      • External course directories
      • Educational Programs
      • Upcoming events
      • Past events
      • Annual meeting
        • Annual meeting 2025
          • Program
          • Sponsors
          • Pictures
        • Annual Consortium Meeting 2024
        • Annual Consortium Meeting 2023
    • Resources
      • Tools
        • ATMP & Regenerative medicine
        • Regulations
        • Costs and lead times
        • Clinical trials
      • Publications
        • All publications
        • News items
        • Scientific articles
      • Newsletters
      • Links
    • Get in touch
    • Click to open the search input field Click to open the search input field Search
    • Menu Menu

    Is the proposed EU General Pharmaceutical Legislation ready to support pharmaceutical innovation?

    News items, Uncategorized
    https://www.dare-nl.nl/wp-content/uploads/2024/07/VWS-rapport-3.jpg 766 799 Simone Punt https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Simone Punt2024-04-30 12:00:482024-08-28 12:10:29Is the proposed EU General Pharmaceutical Legislation ready to support pharmaceutical innovation?

    Rapport Verkenning aanvaardbaar risico gentherapieonderzoek (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/03/Rijksoverheid_3.png 1069 1811 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2024-03-14 16:09:312024-05-27 07:10:10Rapport Verkenning aanvaardbaar risico gentherapieonderzoek (in Dutch)

    NTvH artikel ‘DARE-NL: Nederlands platform voor snellere toegang tot ATMP’s bij kanker’ (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/03/NTVH_3.png 1213 2400 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2024-03-02 11:27:302024-05-27 07:33:03NTvH artikel ‘DARE-NL: Nederlands platform voor snellere toegang tot ATMP’s bij kanker’ (in Dutch)

    Dashboard Doorlooptijden Geneesmiddelen opgezet door VWS (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/02/dashboard-doorlooptijd.png 828 806 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2024-02-02 13:19:112024-04-03 10:53:08Dashboard Doorlooptijden Geneesmiddelen opgezet door VWS (in Dutch)

    Boek uitgebracht over gen- en celtherapie (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/02/Boek-gen-en-celtherapie_2.png 293 192 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2024-02-02 11:49:382024-04-03 10:53:32Boek uitgebracht over gen- en celtherapie (in Dutch)

    Kamerbrief ‘Stimuleren innovatieve geneesmiddelenontwikkeling’ (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/02/tweede-kamer.png 510 825 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2023-12-19 13:08:462024-04-03 10:53:58Kamerbrief ‘Stimuleren innovatieve geneesmiddelenontwikkeling’ (in Dutch)

    Rapport van het Rathenau instituut ‘De genen waar het om gaat – Een verkenning van maatschappelijk verantwoorde ontwikkeling van gentherapie’ (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/02/Rathenau_2.png 638 601 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2023-12-18 13:00:412024-04-03 10:54:28Rapport van het Rathenau instituut ‘De genen waar het om gaat – Een verkenning van maatschappelijk verantwoorde ontwikkeling van gentherapie’ (in Dutch)

    Artikel over ATMP therapie in Pharmaceutisch Weekblad (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/02/pharm.wb_2.png 307 362 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2023-10-03 09:22:002024-04-03 10:55:28Artikel over ATMP therapie in Pharmaceutisch Weekblad (in Dutch)

    Kamerbrief ‘Verkenning naar de mogelijkheden tot het verminderen van de (financiële) obstakels bij drug repurposing’ (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/02/tweede-kamer.png 510 825 Adel Medzikovic https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png Adel Medzikovic2023-08-04 11:58:332024-04-03 10:56:02Kamerbrief ‘Verkenning naar de mogelijkheden tot het verminderen van de (financiële) obstakels bij drug repurposing’ (in Dutch)

    Interview DARE-NL Management Team (in Dutch)

    News items
    https://www.dare-nl.nl/wp-content/uploads/2024/02/MT_interview_4.png 355 397 admin https://www.dare-nl.nl/wp-content/uploads/2022/12/DARE-NL-logo-300x151.png admin2022-05-15 15:35:342024-04-03 10:56:28Interview DARE-NL Management Team (in Dutch)
    Page 3 of 41234

    Contact us at info@dare-nl.nl

    Scroll to top Scroll to top Scroll to top
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    • Manage options
    • Manage services
    • Manage {vendor_count} vendors
    • Read more about these purposes
    View preferences
    • {title}
    • {title}
    • {title}